XHKG
0348
, Last price
HKD
Name
China Healthwise Holdings Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Healthwise Holdings Limited, an investment holding company, engages in the sale of Chinese health products in Hong Kong. It operates through three segments: Chinese Health Products, Money Lending Business, and Investment in Financial Instruments. The company sells Chinese and other pharmaceutical products, health products, ginseng, and dried seafood products to wholesalers and retailers; and trades and retails Sum Yung and dried seafood under the Nam Pei Hong brand. It is also involved in money lending business; and invests in financial instruments. The company was formerly known as Haier Healthwise Holdings Limited and changed its name to China Healthwise Holdings Limited in January 2017. China Healthwise Holdings Limited was incorporated in 1997 and is headquartered in Central, Hong Kong.
Key people
Chairman of the Board · since 2016
Executive Vice Chairman of the Board · since 2017
Lun Leung
Executive Director · since 2014
Chi Keung Tse
Executive Director · since 2016
Huixia Yuan
Executive Director · since 2018
Yuk Hung Leung
Associate Director
Ki Yin Ng
Director and Head - Operation
Bruce Oravec
Director - Kid Galaxy Inc. · since 2002
Ming Wan Lo
Executive Director, Company Secretary · since 2017
Hok Lim Lai
Independent Non-Executive Director · since 2016
Wai Hung Lien
Independent Non-Executive Director · since 2016
Independent Non-Executive Director · since 2016
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||